» Articles » PMID: 12572933

Cardiac and Pulmonary Calcification in a Hemodialysis Patient: Partial Regression 4 Years After Parathyroidectomy

Overview
Journal Clin Nephrol
Specialty Nephrology
Date 2003 Feb 8
PMID 12572933
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: The reversibility of extraskeletal calcifications in dialysis patients is an important and unresolved issue. Although periarticular calcifications have been shown to be reversible, little data are available on vascular or parenchymal calcifications.

Case History: A patient on maintenance hemodialysis with severe hyperparathyroidism, hypercalcemia and hyperphosphatemia was admitted to undergo parathyroidectomy. A preoperative total body bone scintigraphy was performed to better evaluate a lytic lesion in the pelvis, the histology of which proved to be a "brown tumor". The scan showed the typical findings of renal osteodystrophy, but also a diffuse extra-skeletal uptake of bone tracer in the lungs, kidneys, femoral arteries and myocardium. After surgery, good control of serum calcium, phosphate (Ca x P product < 50 mg2/dl2) and PTH levels was maintained during 4 years of follow-up. Bone scans were repeated after 2 and 4 years, showing marked improvement of periarticular uptake at the ends of long bones. Extraosseous calcium deposition was still markedly evident, but progressively decreased (at 4 years: heart -36%, lungs -18%).

Conclusion: In this dialysis patient, extraskeletal calcification of visceral organs (particularly in the heart and the lungs) due to prolonged hypercalcemia and hyperphosphatemia was partially reversible by parathyroidectomy followed by good long-term control of serum phosphate and calcium.

Citing Articles

Extensive myocardial calcifications: a systematic literature review of a rare pathological phenomenon.

Sozzi F, Gnan E, Faggiano A, Giangiacomi F, Iacuzio L, Canetta C Front Cardiovasc Med. 2024; 11:1367467.

PMID: 39135615 PMC: 11317411. DOI: 10.3389/fcvm.2024.1367467.


Oxidative stress and angiogenesis in primary hyperparathyroidism.

Deska M, Romuk E, Segiet O, Bula G, Truchanowski W, Stolecka D Eur Surg. 2017; 49(3):118-126.

PMID: 28596785 PMC: 5438426. DOI: 10.1007/s10353-016-0457-6.


Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease.

Hu P, Xuan Q, Hu B, Lu L, Wang J, Qin Y Int J Biol Sci. 2012; 8(5):663-71.

PMID: 22606047 PMC: 3354624. DOI: 10.7150/ijbs.3886.


Modulation of vitamin D signaling is a potential therapeutic target to lower cardiovascular risk in chronic kidney disease.

Hu P, Hu B, Wang J, Lu L, Qin Y Med Sci Monit. 2011; 17(6):HY14-20.

PMID: 21629196 PMC: 3539536. DOI: 10.12659/msm.881790.


Fetuin-mineral complex reflects extraosseous calcification stress in CKD.

Hamano T, Matsui I, Mikami S, Tomida K, Fujii N, Imai E J Am Soc Nephrol. 2010; 21(11):1998-2007.

PMID: 20947626 PMC: 3014014. DOI: 10.1681/ASN.2009090944.